Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on developing anti-inflammatory therapies for cardiovascular disease (CVD). Their lead product, CardiolRx, is a pharmaceutical manufactured cannabidiol formulation being investigated in a Phase II/III study in hospitalized patients testing positive for COVID-19 with a prior history of, or risk factors for CVD. The company has also initiated an international Phase II trial of CardiolR in acute myocarditis, a main cause of cardiac death in people less than 35 years old. In addition, Cardiol is developing a subcutaneous formulation of CardiolRx for the treatment of inflammation in the heart that is associated with the development and progression of heart failure. The company was founded by David Elsley, Eldon Smith, and Anthony Bolton on January 19, 2017 and is headquartered in Oakville, Canada.